LY3437943 is a novel triple receptor agonist under investigation for its potential clinical benefits. This innovative compound targets three key receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and growth hormone secretagogue receptor (GCG). By activating these receptors, LY3437943 aims to optimize glu